Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trialNicholas C. Turner, Alistair Ring, Jacinta Abraham et al.|The Lancet Oncology|2020Cited by 351
Inactivating <i>NF1</i> Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy ResistanceAlex Pearson, Nicholas C. Turner, Paula Proszek et al.|Clinical Cancer Research|2019Cited by 137
Ranked prediction of p53 targets using hidden variable dynamic modelingMartino Barenco, Michael Hubank|Genome biology|2006Cited by 130
Genomic profile of advanced breast cancer in circulating tumour DNABelinda Kingston, Nicholas C. Turner, Rosalind Cutts et al.|Nature Communications|2021Cited by 95
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i> -Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid CancersJavier Pascual, Nicholas C. Turner, Joline S.J. Lim et al.|Cancer Discovery|2020Cited by 67